TY - JOUR
T1 - International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors
T2 - The EORTC QLQ-SURV100
AU - Fox, Louis
AU - van Leeuwen, Marieke
AU - Jones, Jennifer M.
AU - Al-Omari, Amal
AU - Abaza, Haneen
AU - Al-Khaifi, Muna
AU - Eichler, Martin
AU - Hartup, Sue
AU - Velikova, Galina
AU - Friðriksdóttir, Nanna
AU - Cho, Juhee
AU - Vanlaer, Nathalie
AU - Rogiers, Anne
AU - Costi, Stefania
AU - Soncini, Silvia
AU - Kjær, Trille Kristina
AU - Arndt, Volker
AU - Doege, Daniela
AU - Alkan, Ali
AU - Ishiki, Hiroto
AU - Rammant, Elke
AU - Baumann, Jannike
AU - Sinn, Marianne
AU - Annunziata, Maria Antonietta
AU - Arraras, Juan Ignacio
AU - Van Hemelrijck, Mieke
AU - Pace, Andrea
AU - Clatworthy, Naomi
AU - King, Victoria
AU - Tolstrup, Lærke Kjær
AU - Shimomura, Akihiko
AU - Kontogianni, Meropi
AU - Sodergren, Samantha C.
AU - Vukšić, Nikolina
AU - Petersen, Morten Aagaard
AU - Kieffer, Jacobien M.
AU - Jefford, Michael
AU - Chalk, Tara
AU - Young, Teresa
AU - Borda, Nayanaben
AU - Morag, Ofir
AU - Harle, Amelie
AU - Petranović, Duška
AU - Meggiolaro, Elena
AU - De Padova, Silvia
AU - Jansen, Femke
AU - Turhal, Nazim Serdar
AU - Navarra, Chiara Maria
AU - Baumann, Ingo
AU - Amdal, Cecilie Delphin
AU - Vassiliou, Vassilios S
AU - Pinto, Monica
AU - Kurosawa, Saiko
AU - Vistad, Ingvild
AU - Al-Balushi, Muna
AU - Al-Ghoche, Ahmad
AU - Dirven, Linda
AU - Capela, Andreia
AU - Elsayed, Zeinab
AU - Montemuiño, Sara
AU - Willisch, Patricia
AU - Aaronson, Neil K
AU - van der Poll-Franse, Lonneke
AU - on behalf of the EORTC Quality of Life Group
N1 - Publisher Copyright:
© 2026 The Authors.
PY - 2026/9/9
Y1 - 2026/9/9
N2 - Introduction Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors’ self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. Methods The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1–10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. Results The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings ' 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. Conclusions The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.
AB - Introduction Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors’ self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. Methods The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1–10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. Results The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings ' 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. Conclusions The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.
KW - Cancer
KW - Cancer survivors
KW - Patient-reported outcome measures
KW - Quality of life
KW - Survivorship
UR - https://www.scopus.com/pages/publications/105047072051
U2 - 10.1016/j.ejca.2026.116959
DO - 10.1016/j.ejca.2026.116959
M3 - Journal article
C2 - 42541912
AN - SCOPUS:105047072051
SN - 0959-8049
VL - 245
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 116959
ER -